Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi and Regeneron will appeal jury verdict that Amgen patents are valid; judge to consider permanent injunction.
You may also be interested in...
In A Win For Amgen, Court Blocks Sanofi/Regeneron's Praluent Sales In Germany
A court in Dusseldorf ruled that Praluent infringes a patent for Amgen's better-selling PCSK9 inhibitor Repatha, saying that Sanofi and Regeneron must stop selling their biologic in Germany. It's unclear whether there will be any readthrough to ongoing patent disputes in other countries.
In A Win For Amgen, Court Blocks Sanofi/Regeneron's Praluent Sales In Germany
A court in Dusseldorf ruled that Praluent infringes a patent for Amgen's better-selling PCSK9 inhibitor Repatha, saying that Sanofi and Regeneron must stop selling their biologic in Germany. It's unclear whether there will be any readthrough to ongoing patent disputes in other countries.
PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial
Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.